Reported results
- PEMGARDA net product revenue was $15.4 million for the quarter ended September 30, 2026.
- Research and development expenses were $18.7 million for the quarter ended September 30, 2026.
- Selling, general and administrative expenses were $30.3 million for the quarter ended September 30, 2026.
- Net loss was $33.5 million for the quarter ended September 30, 2026.
- Basic and diluted net loss per share was $0.10 for the quarter ended September 30, 2026.
- Cash and cash equivalents were $126.4 million as of September 30, 2026.
Notes
The U.S. Department of Health and Human Services announced notice of the termination of the Emergency Use Authorization for PEMGARDA, effective June 29, 2027.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.
